Unlocking the Power of Analytical Ultracentrifugation (AUC) in Biopharmaceutical Development 

What Is Analytical Ultracentrifugation?

Analytical Ultracentrifugation (AUC) is a powerful, label-free, matrix-free technique used to analyze the size, shape, interactions, and purity of macromolecules in solution. It separates molecules based on their sedimentation behavior in a centrifugal field, offering detailed insights without the need for immobilization or surface interactions.

• Sedimentation Velocity (SV-AUC): Ideal for determining the size distribution and aggregation state of biopharmaceuticals, including proteins, viruses, nanoparticles, and more.
• Sedimentation Equilibrium (SE-AUC): Used to measure molecular weight and interactions, particularly in self-associating systems or equilibrium-based studies.

AUC is recognized by regulatory agencies like the FDA and EMA as a powerful orthogonal tool — especially for AAV gene therapy vectors, mRNA vaccines, virus-like particles (VLPs), and complex biologics.

Why Is AUC Critical in Drug Development?

Biopharmaceuticals are inherently complex and sensitive to environmental and process-induced changes. Standard techniques like SEC-MALS or DLS may fall short in accurately assessing aggregates or higher-order structures under native conditions. This is where AUC offers a distinct advantage.

Key benefits of AUC in biopharmaceutical development include:

• Native state analysis without interference from surfaces or matrices
• High resolution for detecting and quantifying aggregates, fragments, and empty/full capsid ratios
• Regulatory acceptance as a robust orthogonal method for release testing
• Application across modalities — from monoclonal antibodies to novel delivery platforms like lipid nanoparticles

Coriolis Pharma: Your Expert Partner for AUC Services

At Coriolis Pharma, we have expanded our capabilities to offer GMP-compliant AUC services, including SV-AUC to support:

• Formulation development
• Stability studies
• Comparability assessments
• Release testing of AAV and other advanced biologics

Our investment in AUC technology complements our comprehensive analytical toolbox. We combine deep scientific expertise with state-of-the-art instrumentation and decades of experience in biopharmaceutical characterization.

What sets Coriolis apart?

• End-to-end analytical support: We integrate AUC into a broader analytical strategy tailored to your molecule’s needs and development phase.
• Regulatory-ready data: We provide documentation that supports regulatory submissions and quality assurance.
• Customized study design: Every AUC experiment is tailored to your molecule and its development phase — from early-stage to final product release.

Our AUC services are particularly suited for:

• Gene therapy products
• Monoclonal antibodies and fusion proteins
• Virus-like particles and protein nanoparticles
• Lipid-based nanoparticles

We support clients across the globe — from startups to large pharmaceutical companies — delivering high-quality data, fast turnaround times, and scientific guidance throughout the project lifecycle.

Ready to Elevate Your Analytical Strategy?

With AUC now part of our integrated service portfolio, Coriolis Pharma is ready to help you de-risk development and optimize the quality of your biopharmaceuticals.

Partner with Coriolis Pharma — where science meets innovation in biopharmaceutical analysis.
Contact us today to learn how our AUC services can support your drug development goals.